Anika Therapeutics Files DEF 14A for 2023 Executive Compensation

Ticker: ANIK · Form: DEF 14A · Filed: Jun 11, 2024 · CIK: 898437

Anika Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyAnika Therapeutics, Inc. (ANIK)
Form TypeDEF 14A
Filed DateJun 11, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$166.7 m, $158, $163 million, $101.9 million, $600 million
Sentimentneutral

Sentiment: neutral

Topics: executive-compensation, proxy-statement, corporate-governance

Related Tickers: ANIK

TL;DR

Anika's DEF 14A is out, detailing exec pay & equity awards for 2023. Check Darling & Blanchard comp.

AI Summary

Anika Therapeutics, Inc. filed a DEF 14A on June 11, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation and other corporate governance matters. Key figures include compensation data for individuals like DarlingMember and BlanchardMember, with equity awards valued at year-end.

Why It Matters

This filing provides transparency into how Anika Therapeutics compensates its top executives, which can influence investor decisions and perceptions of company management.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine but can reveal significant information about executive compensation and corporate governance that may impact stock price.

Key Numbers

  • 2023-12-31 — Fiscal Year End (The period covered by the compensation details.)
  • 20240611 — Filing Date (Date the DEF 14A was submitted to the SEC.)

Key Players & Entities

  • Anika Therapeutics, Inc. (company) — Filer of the DEF 14A
  • DarlingMember (person) — Executive compensation recipient
  • BlanchardMember (person) — Executive compensation recipient
  • 0001193125-24-159219 (dollar_amount) — Accession number for the filing

FAQ

What is the total compensation for the named executive officers in 2023?

The filing details compensation components for named executive officers, including equity awards, but specific total dollar amounts for 2023 are not immediately available in the provided snippet.

Who are the key individuals whose compensation is detailed in this filing?

The filing references compensation details for individuals identified as 'DarlingMember' and 'BlanchardMember'.

What type of equity awards are discussed in the filing?

The filing mentions 'FairValueOfEquityAwardsMadeDuringCurrentYear' and 'FairValueAtVestingOfEquityAwardsMadeDuringYearThatAlsoVestedDuringYear'.

What is the purpose of a DEF 14A filing?

A DEF 14A filing (Definitive Proxy Statement) is used to solicit proxies from shareholders for annual or special meetings, typically including information on executive compensation, director nominations, and other corporate governance matters.

When is the shareholder meeting for which this proxy statement is being issued?

The 'CONFORMED PERIOD OF REPORT' is listed as 20240709, indicating the relevant period for the shareholder meeting.

Filing Stats: 4,456 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-06-11 17:05:18

Key Financial Figures

  • $166.7 m — reased revenue for fiscal 2023 by 7% to $166.7 million, above the $158 to $163 million g
  • $158 — 2023 by 7% to $166.7 million, above the $158 to $163 million guidance for the year;
  • $163 million — 7% to $166.7 million, above the $158 to $163 million guidance for the year; Achieved Adjus
  • $101.9 million — ; Generated record annual revenues of $101.9 million in OA Pain Management on global growth
  • $600 million — 4, which together address the more than $600 million U.S. rotator cuff market; Conducted a
  • $1 billion — throplasty portfolio into the more than $1 billion U.S. reverse shoulder market; and 2

Filing Documents

: Gender Identity

Part I: Gender Identity Directors 3 5 1

: Demographic Background

Part II: Demographic Background African American or Black 1 Alaskan Native or Native American Asian Hispanic or Latinx Native Hawaiian or Pacific Islander White 3 4 Two or More Races or Ethnicities LGBTQ+ Persons with Disabilities Visible Minorities Indigenous Peoples Did Not Disclose Demographic Background 1 6 Table of Contents Additional Board Governance Practices Elections: Voting Standard Majority (1) Resignation Policy Yes Mandatory Retirement Age or Tenure No Chair: Separate Chair of the Board and Chief Executive Officer Yes Independent Chair of the Board Yes Robust Responsibilities and Duties Assigned to Independent Chair Yes Meetings: Number of Board Meetings Held in 2023 13 Each of the directors attended at least 75% of the of the Board meetings in 2023 during the director's term Yes Independent Directors Meet without Management Present Yes Number of Standing Committee Meetings Held in 2023 19 Each of the Members Attended at least 75% of the Committee Meetings in 2023 Yes Director Status: All Directors in Compliance with our Overboarding Guidelines Yes Material Related-Party Transactions with Directors None Standing Board Committee Membership Independence 100% Board Oversight of Company Strategy and Risk Yes All Directors in Compliance with Hedging and Pledging Prohibitions Yes All Directors in Compliance with Stock Ownership Guidelines Yes Stockholder Rights: Dual Class Common Stock No Poison Pill No Cumulative Voting No (1) Plurality carve out for contested elections Proposal 2: Ratification of Independent Auditor for 2024 The Audit Committee has approved the retention of Deloitte & Touche LLP as our independent auditor with respect to our consolidated financial statements as of, and for the year ending, December 31, 2024. Board Recommendation: The Board of Directors recommends a vote "FOR" the ratification of Deloitte & Touche LLP

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.